Poloxamer 407-induced atherosclerosis in mice appears to be due to lipid derangements and not due to its direct effects on endothelial cells and macrophages. by Johnston, Thomas P et al.
CORONARY heart disease secondary to atherosclerosis
is still the leading cause of death in the US. Animal
models used for elucidating the pathogenesis of this
disease primarily involve rabbits and pigs. Previous
studies from this laboratory have demonstrated
intraperitoneal injections of poloxamer 407 (P-407)
in both male and female mice will lead to hyperlipi-
demia and atherosclerosis, suggesting the use of this
polymer to develop a mouse model of atherosclero-
sis. In order to understand the mechanism of P-407-
induced hyperlipidemia and vascular lesion forma-
tion, we evaluated the direct effects of P-407 on
endothelial cell and macrophage functions in vitro,
and its in vivo effects on the oxidation of circulating
lipids following long-term (4 month) administration.
Our results demonstrated that incubation of P-407
with human umbilical vein endothelial cells in
culture did not influence either cell proliferation or
interleukin-6 and interleukin-8 production over a
concentration range of 0 
/40 mM. In addition, nitric
oxide production by macrophages was not affected
by P-407 over a concentration range of 0 
/20 mM.
Finally, we demonstrated that while P-407 could not
induce the oxidation of LDL-C in vitro, long-term (4
month) administration of P-407 in mice resulted in
elevated levels of oxidized lipids in the plasma. Thus,
it is suggested that the formation of atherosclerotic
lesions in this mouse model of atherosclerosis does
not result from either direct stimulation of endothe-
lial cells or macrophage activation by P-407. Instead,
these data would support the premise that oxidation
of lipids (perhaps low-density lipoprotein choles-
terol) by an indirect mechanism following injection
of P-407 may represent one of the mechanisms
responsible for atheroma formation.
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Introduction
Death due to coronary heart disease caused by
atherosclerosis continues to be a leading cause of
mortality in affluent nations of the world. The
prevalence is maximally apparent in individuals
with elevated concentrations of low-density lipopro-
tein cholesterol (LDL-C) and a genetic predisposition
to this multifactorial disease.
1,2
To assist in the search for answers to the pathogen-
esis of atherosclerosis, various animal models have
been developed.
3 Atherosclerosis has historically
been studied in rabbits
4 and pigs.
5 However, in
recent years, the mouse has proven to be an
important animal model to dissect many factors that
contribute to atherosclerotic heart disease.
6 While
each animal model has its own particular limitations
and merits, the mouse has emerged as a model with
some definite advantages. Mice are rather inexpen-
sive and are one of the most well-characterized
mammals to date. As such, gene-deficient (‘knock-
out’) mice such as low-density lipoprotein receptor,
apolipoprotein E, and others have been bred to
determine what effect the deletion of a single gene
has on the natural progression of atherosclerosis. The
validity of classic cholesterol-fed rabbit models
would appear questionable since the rabbit is a
herbivore. Fat-fed, non-transgenic mouse models
(e.g. wild-type C57BL/6 mice) typically contain cholic
acid in the diet to induce atheroma formation.
7 Cholic
acid has been cited as a potential proinflammatory
agent to vascular endothelium and may, in and of
itself, be the causative agent for induction of athero-
sclerosis in this model.
6 Thus, it can be seen that no
one animal model is ideal for the study of athero-
sclerotic heart disease, but rather each model has its
own advantages and disadvantages.
Recently, a new mouse model to study mechan-
isms associated with hyperlipidemia and athero-
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The model involves the administration of a non-ionic
surface-active agent (surfactant) called poloxamer
407 (P-407) to either male or female C57BL/6 mice.
One 0.5 g/kg injection of P-407 results in marked
hypercholesterolemia ( /800 mg/dl) and profound
hypertriglyceridemia ( /5000 mg/dl) for greater than
4 days.
8,9,13 The precise degree of both hypercholes-
terolemia and hypertriglyceridemia desired may be
obtained by simple titration of the administered
dose.
8 Long-term administration of P-407 (4 months)
to either sex of this mouse strain produces aortic
atherosclerotic lesions.
13
The P-407 mouse model of hyperlipidemia and
atherosclerosis has several advantages over other
current mouse models of atherosclerosis. For exam-
ple, the P-407 mouse model of atherosclerosis, which
utilizes wild-type C57BL/6 mice, does not require
cholic acid in the diet for lesion formation.
13 In
addition, aortic atherosclerotic lesions are formed in a
time frame equivalent to well-accepted, fat-fed, non-
transgenic models,
13,15,16 the biological activity of key
enzymes involved in lipid metabolism (cholesterol
7a-hydroxylase, lipoprotein lipase, and hepatic li-
pase) are predictably altered,
9,17,18 the model permits
evaluation of the potency of a number of antihyper-
lipidemic drugs of various classes [nicotinic acid,
fibric acid derivatives, and HMG-CoA reductase
inhibitor drugs (statins)],
18 21 and the model allows
for the assessment of pharmacological agents that
may cause regression of P-407-induced atherosclero-
tic lesions.
15
There is overwhelming evidence indicating that
atherosclerosis is a multifactorial disease and involves
inflammatory responses by endothelial cells and
macrophages. The purpose of the present investiga-
tion was to determine whether P-407-induced ather-
osclerosis is strictly associated with lipid
derangements or is also mediated by inflammatory
responses. These variables were studied to better
characterize the P-407 mouse model of atherosclero-
sis in an attempt to identify key factors involved in
atheroma formation in humans. The results presented
in the present report would suggest that the progres-
sion of atherosclerotic lesion formation in C57BL/6
mice treated with P-407 is predominantly due to
increased LDL-C and triglycerides, and may not be
due to direct effects of the polymer on endothelial
cells or macrophage activation.
Materials and methods
Materials
Human umbilical vein endothelial cells (HUVEC)
were obtained from Clonetics (San Diego, CA,
USA). Minimal essential medium and fetal bovine
serum were purchased from Hyclone Laboratories
(Logan, UT, USA). Heparin, N-2-hydroxyethyl-piper-
azine-N?-2-ethanesulfonic acid (HEPES), penicillin,
streptomycin, and lipopolysaccharide (LPS) (Escher-
ichia coli), endothelial cell growth supplement, hu-
man LDL-C (lot number 88H9275), cupric sulfate,
thiobarbituric acid, and ferric chloride were obtained
from Sigma Chemical Co. (St Louis, MO, USA).
Soybean-derived trypsin inhibitor was purchased
from Boehringer Mannheim (Indianapolis, IN, USA).
F-12K medium and trypsin-ethylenediamine tetraace-
tate (EDTA) were obtained from Life Technologies
(Grand Island, NY, USA). The enzyme-linked immu-
nosorbent assay (ELISA) kits for interluekin (IL)-6 and
IL-8 were purchased from R&D Systems, Inc. (Min-
neapolis, MN, USA) and BioSource International
(Camarillo, CA, USA), respectively. Sprague /Dawley
rats (350 /400 g) were obtained from Harlan
Sprague /Dawley (Indianapolis, IN, USA) and 5-
week-old to 6-week-old, female C57BL/6 mice (aver-
age weight /15.29 /1.4 g) were obtained from the
Jackson Laboratory (Bar Harbor, ME, USA). The low-
fat mouse diet (Formulab diet 5008) consisted of 6.5%
fat, 280 ppm cholesterol, linoleic acid (1.4%), lino-
lenic acid (0.09%), arachidonic acid (0.01%), omega-3
fatty acids (0.3%), total saturated fatty acids (2.5%),
and total monounsaturated fatty acids (2.3%) and was
obtained from PMI Nutrition International, Inc.
(Brentwood, MO, USA). The high-fat diet (Diet
number TD-88051) consisted of 12% fat, high-protein
casein (7.5%), dextrose (2.5%), sucrose (1.6%), dex-
trin (0.6%), cocoa butter (7.5%), cholesterol (1.3%),
sodium cholate (0.5%), cellulose (1.3%), Teklad
mineral and vitamin mix (1.1%), and choline chloride
(0.1%), and was supplied by Harlan Teklad (Madison,
WI, USA).
Collection and isolation of peritoneal
macrophages from rats
Three-month-old to four-month-old male Sprague /
Dawley rats were the source of peritoneal macro-
phages. The methods employed for the isolation of
macrophages have been previously described.
22,23
Briefly, the peritoneal cavity of each rat was lavaged
under sterile conditions with Minimum Essential
Medium containing 15 mM HEPES, 100 U/ml peni-
cillin, 100 mg streptomycin, 10% fetal bovine serum
(HMEM), and 5 U/ml heparin. The peritoneal cells
were then pooled, centrifuged at 250 /g for 10 min
at room temperature, and washed twice with HMEM.
Two-milliliter aliquots of the cell suspension [(6 /
8) /10
7 cells) were layered on 4 ml columns of
22.5% (w/v) metrizamide (density 1.125 g/ml) in
HMEM, and centrifuged at 200 /g for 15 min.
Macrophages were collected at the gradient interface,
and mast cells were sedimented at the bottom. The
macrophage fractions were collected, pooled,
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phages collected by this procedure exceeded 95% in
purity and viability when tested by trypan blue
exclusion.
Culture of HUVEC
HUVEC were grown in endothelial cell growth
medium (EGM-2MV) supplemented with the recom-
mended growth factors (Clonetics) and 5% fetal
bovine serum.
24 At confluence, the cells were de-
tached from the culture flasks using trypsin-EDTA,
washed twice, and re-suspended in complete culture
medium. All experiments described employed cells
between five to eight passages.
Determination of the production of IL-6 and IL-8
by HUVEC
The quantification of IL-6 and IL-8 production by
HUVEC was conducted as previously described.
25
Briefly, HUVEC (2 /10
4) were added to each well of
a 96-well flat-bottom microtiter plate and allowed to
adhere for 24 h in EGM complete medium. After the
cell adherence, P-407 (0 /40 mM), LPS (50 ng/ml), P-
407  /LPS, or medium was added to HUVEC mono-
layers and the final volume adjusted to 0.2 ml with
complete EGM. All incubations were carried out at
378Ci naC O 2 incubator for 24 or 48 h unless
otherwise indicated. After the incubation, aliquots
of the culture supernatants were collected, appro-
priately diluted, and assayed for IL-6 and IL-8
according to the instructions provided by the ELISA
kit manufacturers. The cytokine levels were quanti-
fied by comparison with a standard curve run
concurrently, utilizing recombinant human IL-6 and
IL-8.
Endothelial cell proliferation assay
The direct effect of P-407 on endothelial cell pro-
liferation was determined by quantifying total cellular
nucleic acid content using a commercially available
assay kit (Molecular Probes, Eugene, OR, USA),
according to the manufacturer’s instructions. Briefly,
HUVEC (2 /10
4) were added to each well of a 96-
well flat-bottom microtiter plate and allowed to
adhere for 24 h in complete EGM. After cell
adherence, P-407 (0 /40 mM), LPS (50 ng/ml), P-
407  /LPS, or medium was added to HUVEC mono-
layers and the final volume adjusted to 0.2 ml with
complete EGM. After incubation at 378Ci naC O 2
incubator for 24 or 48 h, the cells were washed twice
with Hank’s balanced salt solution. Next, 200 ml
appropriately diluted Cyquant
TM reagent (Molecular
Probes) was added to each of the wells and the plates
incubated in darkness for 5 min at room temperature.
The intensity of fluorescence was measured at
excitation and emission wavelengths of 480 nm and
520 nm, respectively, using a Model f-max microtiter
plate fluorescence reader (Molecular Devices Corp.,
Sunnyvale, CA, USA).
Measurement of nitric oxide production from rat
peritoneal macrophages
Peritoneal macrophages from rats were obtained via
peritoneal lavage as already described and descried
previously.
22 Briefly, 0.2 ml aliquots of the cell
suspension containing 2 /10
5 macrophages were
added to each of the wells of a 96-well culture plate
and allowed to adhere for 2 h. Next, the non-
adherent cells were removed by washing with
HMEM. Macrophage monolayers were incubated at
378C for 18 h with varying concentrations of P-407 (0,
1.25, 2.5, 5, 10, and 20 mM) both in the presence (50
ng/ml) and absence of LPS [a known inducer of nitric
oxide (NO) production]. Synthesis and release of
nitric oxide by macrophages were determined by
assay of culture supernatants for nitrite content using
Griess reagent as previously described.
26
Lipid oxidation studies
P-407 was evaluated over a concentration range of
0.001 /10,000 mM for its capacity to oxidize LDL-C in
vitro using the thiobarbituric acid reactive substances
(TBARS) assay.
27 LDL-C alone served as a negative
control while LDL-C  /cupric sulfate (CuSO4) served
as a positive control. The absorbance values for
aqueous P-407 solutions over the concentration
range 0.001 /10,000 mM was also determined. Finally,
the contribution, if any, of P-407 to the absorbance
values obtained with LDL-C  /CuSO4 was determined
to assess whether P-407 could either oxidize LDL-C
when in the presence of CuSO4 or enhance the
capacity of CuSO4 to oxidize LDL-C. It should be
noted that the commercially obtained LDL-C solution
was first dialyzed to remove EDTA, which would
interfere with copper-induced oxidation of LDL-C. All
solutions were then analyzed using the TBARS assay
according to the method of Schmedes and Hølmer
27
described in brief in the following.
Solution A required for the TBARS assay was
prepared by dissolving 233 mg thiobarbituric acid
in 4 ml doubly deionized water. Next, approximately
36 ml glacial acid was added to bring the total volume
to 40 ml. Solution B utilized in the TBARS assay was
prepared by combining 127 mg sodium sulfite and
2.93 mg FeCl3 in a total volume of 2.33 ml.
Solution A and Solution B were combined no more
than 30 min prior to conducting the assay. To
perform the TBARS assay, dialyzed samples of LDL-
C (214 mg; 31 ml of a 6.9 mg/ml solution) were added
to 10 ml pyrex test tubes with a screw cap. To tubes
that evaluated the effect of P-407 on the oxidation of
Poloxamer 407-induced atherosclerosis in mice
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was added to individual tubes that contained 31 ml
LDL-C. To the four test tubes that served as the
negative control, 200 ml water was added to the 31 ml
LDL-C. The four tubes that served as the positive
control contained 200 ml of 10 mM CuSO4  /31 ml
LDL-C. Finally, tubes that evaluated either the effect
of P-407 on the assay procedure or the effect of P-407
when combined with LDL-C  /CuSO4 contained
either 200 ml of each P-407 concentration evaluated
plus 31 ml water or 100 ml of 10 mM CuSO4, 100 mlo fa
2 /concentration of each P-407 solution prepared
earlier, and 31 ml LDL-C, respectively. To each test
tube in these five groups was added an additional 102
ml CHCl3 to bring the entire volume of an individual
test tube to 333 ml. All tubes were then incubated
overnight (18 h) at 378C.
Following the overnight incubation, 533 ml of the
combined solutions A and B (see earlier) was added
to each tube. The tubes were then capped tightly and
boiled for 30 min followed by placement in cool
water to obtain room temperature. Next, 333 mlo fa
10% trichloroacetic acid was added to each tube and
the contents vortexed for 30 sec. The contents of each
tube were then individually transferred to separate
1.5 ml polypropylene eppendorf tubes, centrifuged at
2000 rpm for 10 min, and then the supernatant
transferred into 1.5 ml disposable cuvettes. The
absorbance of each solution was then determined
at 532 nm using a Beckman DU 7400 UV/vis spectro-
photometer (Fullerton, CA, USA).
Quantification of oxidized lipids in the plasma of
mice treated with P-407
Treatment groups comprised eight mice injected
intraperitoneally with normal saline every third day
for 4 months, eight mice injected intraperitoneally
with P-407 (0.5 g/kg) every third day for 4 months,
and eight mice fed a high-fat, high-cholesterol diet
for 4 months. Blood samples were obtained by
periorbital bleeding at the 4-month sacrifice date
from each of the three treatment groups, the plasma
harvested, and the plasma immediately analyzed for
oxidized lipids using the TBARS assay. In the
analysis, 167 ml plasma collected from each of six
mice in each group was combined with an equal
volume of CHCl3 and individually assayed as already
described. These results were expressed as the mean
OD 9 /the standard deviation of six mice. Mice in all
groups were housed (three animals/cage) under
controlled conditions at temperatures between 21
and 238C. The animals were provided unrestricted
access to water and the appropriate mouse chow
described earlier throughout the 4-month study. All
procedures for P-407 administration and subsequent
blood collection were in accordance with the institu-
tion’s guide for the care and use of laboratory
animals, and the treatment protocol was approved
by the Animal Care Committee at the University of
Missouri-Kansas City.
Data analysis
All data presented in this study are expressed as the
mean9 /standard deviation of the mean value. Statis-
tical analysis consisted of the Student’s t-test for
comparing two mean values and a one-way analysis
of variance (ANOVA) when more than two mean
values were compared. If a value of pB/0.05
associated with an F value was obtained following
the ANOVA, a post hoc analysis was performed
according to the method of Scheffe ´ to identify




To evaluate the direct effect of P-407 on endothelial
cell proliferation, HUVEC were cultured for 24 and 48
h with varying concentrations of the polymer, includ-
ing concentrations that spanned the maximum
plasma concentration obtained following a standard
0.5 g P-407/kg body weight injection to mice.
10 As
evident from the data presented in Table 1, the
relative fluorescence units obtained from cells incu-
bated with P-407 were not significantly (p /0.05)
different from values obtained from control cells
(cells not incubated with P-407) regardless of the
presence of LPS, indicating that P-407 does not alter
endothelial cell proliferation or cell viability. The
presence of LPS in the HUVEC culture did not result
in a significant increase in cell proliferation either in
the absence or presence of P-407 when compared
with corresponding values for control HUVEC (no
LPS) at both 24 and 48 h (Table 1).
Production of IL-6 and IL-8 by HUVEC in vitro
The direct effect of P-407 on the production of
proinflammatory cytokines was assessed by monitor-
ing the release of IL-6 and IL-8 from HUVEC treated
with P-407. The results demonstrated that P-407, over
a concentration range of 0 /40 mM, had no effect on
the production of IL-6 by HUVEC (Fig. 1). The
average concentration of IL-6 detected when HUVEC
were cultured in the presence of P-407 (0 /40 mM)
was approximately 100 pg/ml regardless of whether
IL-6 concentrations were determined after 24 or 48 h
of incubation. On the other hand, incubation of
HUVEC with LPS (50 ng/ml) stimulated HUVEC to
produce IL-6 (400 pg/ml). Incubation of HUVEC
monolayers with P-407 in the presence of LPS did
not further enhance IL-6 production. The results
T. P. Johnston et al.
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HUVEC nor modulates the cytokine production that
was induced by LPS.
As can be noted in Fig. 2, no significant (p /0.05)
difference in IL-8 production was observed between
naive and P-407-treated HUVEC after 24 h in culture.
As expected, the addition of 50 ng/ml LPS to the cell
culture induced a significant increase in IL-8 release
with mean IL-8 concentrations of approximately 5000
pg/ml and 13,000 pg/ml, for the naive and LPS-
treated cells, respectively (Fig. 2). Again, P-407 was
ineffective at activating IL-8 production by naive or
LPS-stimulated endothelial cells.
Effect of P-407 on rat peritoneal macrophage NO
production
The production of NO by macrophages plays a
significant role in vascular physiology and athero-
sclerosis. Therefore, in the present study, the effect of
P-407 on NO production by rat peritoneal macro-
phages was evaluated. The basal level of NO
production by unactivated macrophages was 2.509 /
0.41 mM and was not significantly affected by the
addition of P-407 in the concentration range of 1.25 /
20 mM (Fig. 3). As expected, the addition of LPS to the
macrophage cell culture resulted in an increase in NO
production (19.99 /0.85 mM). In the presence of 5 /20
mM P-407, LPS-induced NO production by macro-
phages was decreased in a dose-dependent fashion.
Extent of lipid oxidation in vitro and in vivo
As shown in Fig. 4, the mean absorbance value
associated with an aqueous solution of P-407 over the
concentration range of 0.001 /10,000 mM was ap-
proximately 0.024. The mean absorbance value for
the solution of LDL-C alone was 0.289 /0.037 and was
not significantly different when compared with the
mean values of the absorbance for solutions that
contained both P-407 and LDL-C (Fig. 4). The latter
solutions had a mean absorbance value of approxi-
mately 0.3. Only the positive control (i.e. the solution
that contained LDL-C, 10 mM CuSO4, and 0.0 mMP -
407) demonstrated an increase in the mean absor-
bance value to 0.549 /0.063. This mean absorbance
value was not statistically different from the mean
absorbance values obtained for the LDL-C and 10 mM
Table 1. Effect of P-407 on proliferation of HUVEC at 24 and 48 h
Concentration of
P-407 (mM)
24 h 48 h
No LPS LPS (50 ng/ml) No LPS LPS (50 ng/ml)
0.0 10.459 /0.18 9.349 /0.44 10.979 /1.82 11.799 /1.87
1.25 11.379 /0.93 9.739 /0.94 9.549 /1.15 9.469 /1.77
2.5 11.669 /1.38 8.689 /0.15 10.789 /2.27 10.179 /1.63
5.0 12.019 /1.19 10.089 /0.66 90839 /1.92 9.649 /1.51
10 11.029 /0.69 10.129 /1.07 9.159 /1.35 9.969 /0.75
20 11.239 /1.02 10.339 /0.63 10.669 /1.83 10.199 /1.92
40 10.989 /0.76 9.849 /0.72 11.389 /2.41 12.829 /1.48
FIG. 1. Effect of P-407 on IL-6 release from HUVEC. Concen-
tration of IL-6 in the absence of LPS at 24 h (solid line, j) and
48 h (solid line, m), and in the presence of LPS (50 ng/ml) at
24 h (dashed line, j) and 48 hr (dashed line, m).
FIG. 2. Effect of P-407 on IL-8 release from HUVEC. Concen-
tration of IL-8 in the absence (solid line, j) and the presence
(dashed line, j) of LPS (50 ng/ml) at 24 h.
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concentration range shown in Fig. 4. The mean
absorbance values for the LDL, 10 mM CuSO4, and
P-407 solutions shown in Fig. 4 were approximately
0.55 and were significantly (pB/0.05) increased
compared with corresponding absorbance values
for solutions that contained either LDL-C alone
(0.289 /0.037) or LDL-C  /P-407 ( /0.3).
As can be noted in Fig. 5, the mean absorbance
value associated with plasma obtained from mice
treated with normal saline for 4 months was 0.529 /
0.01, compared with the values of 0.269 /0.12 and
2.219 /0.33 for plasma samples obtained from mice
that were either fed the high-fat diet or treated with
0.5 g/kg P-407 for 4 months, respectively. It should
FIG. 3. Effect of P-407 on the release of NO from rat peritoneal macrophages in the absence (I) and presence (j) of LPS (50
ng/ml) at 24 h. * Signiﬁcant (pB/0.05) decrease in the NO released when individually compared with the NO concentration
determined at 0 mM P-407.
FIG. 4. The effect of P-407 on the oxidation of human low-
density lipoprotein (LDL) in vitro.( ') LDL alone, (%) LDL  /10
mM CuSO4,( j) P-407  /H2O, (m) LDL  /P-407, and (") LDL  /
CuSO4  /P-407. All data points represent the mean value9 /
standard deviation (n /4). * Signiﬁcant (pB/0.05) increase in
the absorbance values relative to mean values for LDL alone
and LDL  /P-407.
FIG. 5. The effect of a high-fat diet or P-407 treatment on the
extent of lipid oxidation in C57BL/6 mice. All bars represent
the mean value9 /standard deviation (n /6). * Signiﬁcant
(PB/0.05) decrease (high-fat) or increase (P-407 treatment) in
the mean absorbance value when individually compared
with saline-treated controls. # Signiﬁcant (pB/0.05) increase
compared with the mean absorbance value for mice that
consumed the high-fat diet. The mean absorbance value for
P-407-treated mice was obtained following a nine-fold dilu-
tion of the plasma sample.
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152 Mediators of Inflammation Vol 12  2003be emphasized that the plasma samples obtained
from mice treated with P-407 were diluted nine-fold
prior to their analysis using the TBARS assay (Fig. 5).
Both the extent of oxidation of lipids contained in the
plasma of either fat-fed mice or mice treated with P-
407 (as reflected by the respective mean OD values)
were significantly (pB/0.05) different when com-
pared with the corresponding mean value for sal-
ine-treated mice. In the case of the mice fed the high-
fat diet, the degree of lipid oxidation was less than
the lipid oxidation determined for control mice,
whereas with P-407-treated mice the opposite trend
was observed (Fig. 5).
Discussion
The present investigation has attempted to elucidate
several variables that may potentially be associated
with atheroma formation in the P-407 mouse model
of hyperlipidemia and atherosclerosis. In the present
study, P-407 was evaluated for its potential to
modulate endothelial cell and macrophage functions.
P-407 over the concentration range of 0 /40 mM had
no significant effect on the proliferation of human
endothelial cells in culture. This was not entirely
unexpected since P-407 has previously been used in
various biomedical applications. For example, Wang
and Johnston
29 utilized this agent to sustain the
release of recombinant IL-2 from an injectable IL-2/
P-407 gel formulation in rats. Prior to their investiga-
tion in rats, Johnston et al.
30 investigated whether IL-
2, when formulated with P-407, would still retain its
ability to induce proliferation of peripheral blood
lymphocytes (PBL) in culture. The proliferation of
PBL was unaffected by addition of P-407 below a
concentration of 80 mM or approximately 0.1% w/
w.
30 In addition, P-407 has been used in cell cultures
and in vivo, and has not mediated lysis of myo-
cytes,
31 erythrocytes
29 33 and hepatocytes.
34 The
potential of P-407, a non-ionic surface active agent,
to decrease the surface tension in a cell culture could
potentially affect cell-to-cell contact, and therefore
affect proliferation. However, inclusion of P-407 at a
concentration less than or equal to 40 mM did not
affect the proliferation of human endothelial cells in
culture.
The present study also demonstrated that P-407,
over the concentration range 0 /40 mM, had no
capacity to stimulate either IL-6 or IL-8 production
by HUVEC, although the cells responded well to LPS.
Both IL-6 and IL-8 are inflammatory cytokines
produced by endothelial cells, smooth muscle cells,
and macrophages.
35 40 As reported by Rus et al.,
41
the presence of IL-6 and IL-8 in the arterial wall
where complement activation has also occurred
clearly demonstrates the involvement of inflamma-
tory events in the initiation and progression of
atherosclerosis. Thus, it would appear that P-407 is
not proinflammatory to endothelial cells in the
vasculature of mice utilized in the P-407-induced
mouse model of atherosclerosis. This is fortuitous
and perhaps a distinct advantage over fat-fed murine
models that must incorporate cholic acid (a potential
proinflammagen
6) in the diet to induce aortic lesions.
However, it must be noted that oxidized LDL can also
induce and modulate the expression of inflammatory
cytokines.
42 However, we found no increase in the
concentrations of IL-6 and IL-8 in the plasma from P-
407-treated mice (data not shown). Future experi-
ments will determine whether P-407 specifically
induces the oxidation of LDL-C in mice.
The production of NO by unactivated macro-
phages was not affected by P-407 over the concen-
tration range of 0 /20 mM. As expected, incubation of
macrophages with LPS markedly elevated NO pro-
duction. P-407 did not modulate LPS-induced NO
production up to a concentration of 2.5 mM. How-
ever, P-407 above a concentration of 2.5 mM was
inhibitory in a dose-dependent fashion. Nitric oxide
is a free radical with an unpaired electron in the
highest orbital and has been shown to exhibit both
pro-oxidant and anti-oxidant properties.
43,44 In vitro,
NO is able to inhibit lipid peroxidation. However, NO
is rapidly inactivated by the superoxide anion (O2
+)
to form peroxynitrite (ONOO
 ), which is a potent
pro-oxidant. This is the mechanism that accounts for
the oxidation of LDL-C that occurs when NO and O2
+
are simultaneously present in the medium. As NO
and O2
+ are simultaneously released by activated
macrophages, the balance between these two radi-
cals determines the net effect of NO on lipid
peroxidation.
44 Thus, an excess of NO will favor
inhibition of lipid peroxidation while an excess of
O2
+ or equimolar concentrations of NO and O2
+ will
induce lipid peroxidation.
44 With these relationships
in mind, it was interesting to note a significant (pB/
0.05) decrease in NO production by macrophages co-
cultured with LPS and P-407 concentrations ]/5 mM
(Fig. 3). A decrease in NO production would tend to
favor lipid peroxidation. However, we were not able
to conclude unequivocally that P-407 at concentra-
tions ]/5 mM was directly responsible for the
decrease in NO produced by macrophages stimulated
with LPS. It may be that P-407 interfered with the
activity of LPS to stimulate NO production by
macrophages at higher P-407 concentrations (]/5
mM). In contrast, it should be noted that P-407 did not
interfere with the activity of LPS to stimulate cytokine
(IL-6 and IL-8) production by HUVEC in culture (Figs.
1 and 2), suggesting that inactivation of LPS or
competition with LPS may not be the cause. Addi-
tional experimentation is required to determine
whether the decrease in NO production observed
with P-407 at concentrations ]/5 mM was accompa-
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superoxide anion, O2
+. In vivo, an inhibition of NO
production by P-407 may result in vasoconstriction,
as NO is known to cause vasodilation.
Rather than P-407 functioning as a proinflamma-
tory agent with respect to endothelial cells, this
compound appears to indirectly result in the oxida-
tion of plasma lipids in P-407-treated mice. Direct
action of P-407 to oxidize LDL-C was excluded, since
P-407 did not oxidize LDL-C in vitro (Fig. 4). The P-
407 concentration range shown in Fig. 4 spanned the
maximum plasma concentration of P-407 detected in
rodents following a single 0.5 g/kg injection of P-
407.
10 In contrast to our in vitro results, plasma from
mice treated with P-407 for 4 months revealed a
preponderance of oxidized lipids, but not necessarily
LDL-C. The TBARS assay lacks specificity for any one
lipoprotein associated with cholesterol or triglycer-
ides. Instead, it can only detect the presence of
oxidized lipids. However, we have reason to believe
that the oxidized lipids may represent oxidized LDL-C
since preliminary studies have detected antibodies
for malondialdehyde /LDL-C (T.P. Johnston and G.K.
Hansson, unpublished findings), and we have pre-
viously shown that P-407 treatment in mice induced a
shift in the lipoprotein distribution from high-density
lipoprotein cholesterol to predominantly LDL-C and
from very-low-density lipoprotein cholesterol.
14
Combined with the data that demonstrated a de-
crease in the production of NO by macrophages at P-
407 concentrations ]/5 mM, it may suggest that P-407,
by profoundly elevating plasma lipids, indirectly
ensures that some of the lipids will undergo oxida-
tion. It is well-known that lipoprotein oxidation plays
a key role in atherosclerosis. LDL is oxidized in
tissues, including the artery wall, and serves to
stimulate the release of oxidation products that
activate an inflammatory response.
45,46 Thus, the P-
407 mouse model of atherosclerosis may hold
promise as a non-transgenic, non-diet-induced ani-
mal model of atherosclerosis with which to study the
complex mechanisms associated with lipid oxidation
and atheroma formation as well as evaluate the
efficacy of newer antioxidant drugs.
In conclusion, we have demonstrated that P-407
does not appear to have any inherent proinflamma-
tory activity as suggested by its inability to induce IL-6
or IL-8 by HUVEC. Additionally, P-407 neither directly
oxidized human LDL-C nor modified CuSO4-
mediated lipid oxidation in vitro. However, plasma
from P-407-treated mice demonstrated an abundance
of oxidized lipids, but not necessarily only oxidized
LDL-C. Coupled with the decrease in NO production
by cultured macrophages at P-407 concentrations ]/
5 mM, P-407 may potentially induce atherosclerosis in
male and female C57BL/6 mice by markedly elevat-
ing plasma lipids, disturbing the balance between NO
and O2
+, and indirectly causing excess lipids to
undergo oxidation. These findings would seem
more closely aligned with the ‘modified’ (oxidized)
LDL-C theory for the pathogenesis of atherosclerosis,
and may offer a valuable new mouse model for the
study of human coronary heart disease and the
benefits associated with effective antioxidant drug
therapy.
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